Recent Company News

• 10:00 AM ET Oct 24, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (159 total)

• 10:01 AM ET Oct 17, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (62 total)

• 04:23 PM ET Aug 11, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:04 AM ET Oct 15, 2025
  

  Belite Bio announces China NMPA agrees to NDA with priority review based on interim analysis results for the treatment of Stargardt disease with tinlarebant ($79.26, 0.00)

• 08:04 AM ET Sep 12, 2025
  

  Belite Bio announces completion of Phase 3 DRAGON trial of oral tinlarebant ($68.55, 0.00)

• 08:07 AM ET Sep 08, 2025
  

  Belite Bio announces up to $275M upsized private placement; $125M financing upfront with up to an additional $150M tied to exercise of warrants ($65.74, 0.00)

• 08:18 AM ET Aug 11, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:02 AM ET Aug 11, 2025
  

  Belite Bio reports Q2 EPS ($0.31) vs FactSet ($0.41) [5 est, ($0.48)-(0.30)] ($69.88, 0.00)